Mesa Laboratories MLAB Business Segments
| Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Biopharmaceutical Development | $8.85M-38.4% | $14.37M+3.3% | $13.92M+21.2% | $11.49M-9.0% | $12.62M+3.1% | |
| Clinical Genomics | $12.18M+3.5% | $11.77M+5.6% | $11.14M+8.2% | $10.3M-10.5% | $11.51M-9.1% | |
| Revenue by Product | ||||||
| Service | $12.2M+10.4% | $11.05M-2.1% | $11.29M+0.8% | $11.2M+2.2% | $10.96M+7.1% | |
| Revenue by Geography | ||||||
| CN | $4.06M-28.1% | $5.65M+6.2% | $5.32M-2.1% | $5.43M+7.7% | $5.04M-20.3% | |
| Other | $29.61M+0.1% | $29.59M+13.3% | $26.12M-1.3% | $26.47M+2.2% | $25.89M-0.6% | |
| US | $30.06M+0.6% | $29.89M+2.0% | $29.3M+6.0% | $27.65M-11.4% | $31.2M+2.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Mesa Laboratories break its business down?
- Mesa Laboratories (MLAB) reports revenue by business across 3 parts — Biopharmaceutical Development, Calibration Solutions and Clinical Genomics. Each is extracted from the segment footnotes and tracked over time.
- Where does Mesa Laboratories's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Mesa Laboratories's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
